IndraLab

Statements

BAP1 inhibits ASXL1. 1 / 1

| 1

reach

"Recently, BAP1 catalytic inhibitors have been developed that inhibit ASXL1‐driven leukaemic gene signatures and impaired tumour progression in an in vivo model of ASXL1 AML [22]."

37872885

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

BAP1 inhibits ASXL1. 1 / 1

INDRA sources:

Databases

Reading